Credit Suisse analyst Omotayo Okusanya upgrades Phillips Edison (NASDAQ:PECO) from Neutral to Outperform.
Kala Pharma Reveals Safety Data From Stem Cell Therapy Trial For Corneal Defect Impacting Around 240K People In Developed Nations
Kala Pharmaceuticals Inc (NASDAQ:KALA) announced safety data from the first cohort of the CHASE Phase 2b clinical trial evaluating KPI-012, a…